MRI-guided clinical 6-MV radiosensitization of glioma using a unique gadolinium-based nanoparticles injection

Camille Verry (1, 2) , Sandrine Dufort (3, 4) , Emmanuel Luc Barbier (2) , Olivier Montigon (2) , Michel Peoc'H (5) , Philippe Chartier (1) , François Lux (6) , Jacques Balosso (1) , Olivier Tillement (6) , Lucie Sancey (6) , Géraldine Le Duc (4)

1 UGA UFRM - Université Grenoble Alpes - UFR Médecine
2 GIN - [GIN] Grenoble Institut des Neurosciences
3 Nano-H SAS
4 NH TherAguix SA [Meylan]
5 Department of Pathology
6 ILM - Institut Lumière Matière [Villeurbanne]

Aim: This study reports the use of gadolinium-based AGuIX nanoparticles (NPs) as a theranostic tool for both image-guided radiation therapy and radiosensitization of brain tumors. Materials & methods: Pharmacokinetics and regulatory toxicology investigations were performed on rodents. The AGuIX NPs’ tumor accumulation was studied by MRI before 6-MV irradiation. Results: AGuIX NPs exhibited a great safety profile. A single intravenous administration enabled the tumor delineation by MRI with a T1 tumor contrast enhancement up to 24 h, and the tumor volume reduction when combined with a clinical 6-MV radiotherapy. Conclusion: This study demonstrates the efficacy and the potential of AGuIX NPs for image-guided radiation therapy, promising properties that will be assessed in the upcoming Phase I clinical trial.

Mots clés: clinical 6-MV radiation therapy; MRI-guided radiation therapy; radiosensitizing nanoparticles; radiosensitizing nanoparticles future science group

Domaines: Cancer; Physique Médicale [physics.med-ph]; Imagerie

Camille Verry, Sandrine Dufort, Emmanuel Luc Barbier, Olivier Montigon, Michel Peoc'H, et al.. MRI-guided clinical 6-MV radiosensitization of glioma using a unique gadolinium-based nanoparticles injection. Nanomedicine, 2016, 11 (18), pp.2405-2417. ⟨10.2217/nnm-2016-0203⟩. ⟨hal-01405486⟩